Loricera Javier, Calvo-Río Vanesa, Ortiz-Sanjuán Francisco, González-López Marcos A, Fernández-Llaca Hector, Rueda-Gotor Javier, Gonzalez-Vela Maria C, Alvarez Lino, Mata Cristina, González-Lamuño Domingo, Martínez-Taboada Victor M, González-Gay Miguel A, Blanco Ricardo
From the Divisions of Rheumatology (JL, VC-R, FO-S, JR-G, CM, VMM-T, MAG-G, RB), Dermatology (MAG-L, HF-L), Pathology (MCG-V), and Pediatrics (LA, DG-L), Hospital Universitario Marqués de Valdecilla, IFIMAV, Santander, Spain.
Medicine (Baltimore). 2013 Nov;92(6):331-343. doi: 10.1097/MD.0000000000000009.
Cutaneous vasculitis may be associated with malignancies, and may behave as a paraneoplastic syndrome. This association has been reported in a variable proportion of patients depending on population selection. We conducted the current study to assess the frequency, clinical features, treatment, and outcome of paraneoplastic vasculitis in a large unselected series of 766 patients with cutaneous vasculitis diagnosed at a single university hospital. Sixteen patients (10 men and 6 women; mean age ± standard deviation, 67.94 ± 14.20 yr; range, 40-85 yr) presenting with cutaneous vasculitis were ultimately diagnosed as having an underlying malignancy. They constituted 3.80% of the 421 adult patients. There were 9 hematologic and 7 solid underlying malignancies. Skin lesions were the initial clinical presentation in all of them, and the median interval from the onset of cutaneous vasculitis to the diagnosis of the malignancy was 17 days (range, 8-50 d). The most frequent skin lesions were palpable purpura (15 patients). Other clinical manifestations included constitutional syndrome (10 patients) and arthralgia and/or arthritis (4 cases). Hematologic cytopenias (11 cases) as well as immature peripheral blood cells (6 cases) were frequently observed in the full blood cell count, especially in those with vasculitis associated with hematologic malignancies. Specific treatment for vasculitis was prescribed in 10 patients; nonsteroidal antiinflammatory drugs (4 patients), corticosteroids (3 patients), chloroquine (1 patient), antihistamines (1 patient), and cyclophosphamide (1 patient). Ten patients died due to the malignancy and 6 patients recovered following malignancy therapy. Patients with paraneoplastic vasculitis were older, more frequently had constitutional syndrome, and less frequently had organ damage due to the vasculitis than the remaining patients with cutaneous vasculitis. In summary, cutaneous paraneoplastic vasculitis is an entity not uncommonly encountered by clinicians. The most common underlying malignancy is generally hematologic. In these cases the presence of cytopenias and immature cells may be red flags for the diagnosis of cancer. In patients with paraneoplastic cutaneous vasculitis, the prognosis depends on the underlying neoplasia.
皮肤血管炎可能与恶性肿瘤相关,并可能表现为副肿瘤综合征。根据人群选择的不同,这种关联在不同比例的患者中已有报道。我们开展了本研究,以评估在一所大学医院确诊的766例未经选择的皮肤血管炎患者中,副肿瘤性血管炎的发生率、临床特征、治疗及预后。16例(10例男性和6例女性;平均年龄±标准差,67.94±14.20岁;范围,40 - 85岁)表现为皮肤血管炎的患者最终被诊断患有潜在恶性肿瘤。他们占421例成年患者的3.80%。有9例血液系统恶性肿瘤和7例实体恶性肿瘤。皮肤病变是所有患者的初始临床表现,从皮肤血管炎发作到恶性肿瘤诊断的中位间隔时间为17天(范围,8 - 50天)。最常见的皮肤病变是可触及的紫癜(15例患者)。其他临床表现包括全身症状(10例患者)和关节痛及/或关节炎(4例)。全血细胞计数中经常观察到血细胞减少(11例)以及外周血未成熟细胞(6例),尤其是在与血液系统恶性肿瘤相关的血管炎患者中。10例患者接受了血管炎的特异性治疗;非甾体抗炎药(4例患者)、糖皮质激素(3例患者)、氯喹(1例患者)、抗组胺药(1例患者)和环磷酰胺(1例患者)。10例患者因恶性肿瘤死亡,6例患者在接受恶性肿瘤治疗后康复。与其余皮肤血管炎患者相比,副肿瘤性血管炎患者年龄更大,更常出现全身症状,因血管炎导致器官损害的情况较少。总之,皮肤副肿瘤性血管炎是临床医生并不少见的一种疾病。最常见的潜在恶性肿瘤通常是血液系统的。在这些病例中,血细胞减少和未成熟细胞的存在可能是癌症诊断的警示信号。在副肿瘤性皮肤血管炎患者中,预后取决于潜在的肿瘤。